Pasritamig not checked

Janssen Research & Development, LLC · JNJ-78278343 · KLK2-CD3

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
9 active
9 in total · 5 in the EU
Targets
 

What this is

How it works
An antibody built to latch onto two or more targets at once.-mig: multi-specific immunoglobulins WHO name stem
How it’s given
“Pasritamig will be administered in accordance with the procedures specified in the study protocol.”In the company’s words, NCT07871435 on ClinicalTrials.gov
Tested for
Prostatic Neoplasms (5 trials), Prostatic Neoplasms, Castration-Resistant, Metastatic Castration-resistant Prostatic Neoplasms, Metastatic Castration-resistant Prostate Cancer (mCRPC), Adenocarcinoma, Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer
Main trialPhase 3
“The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or death due to any cause) when compared to treatment with docetaxel in participants with metastatic castrate-resistant prostate cancer (mCRPC; a cancer of prostate, a male reproductive gland found below the bladder, that grows despite low levels of male hormones).”In the company’s words, NCT07225946 on ClinicalTrials.gov
Other names
JNJ-78278343 · KLK2-CD3

Other drugs for Prostatic Neoplasms

All 195 drugs for Prostatic Neoplasms

Coming up9

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials9

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 19 Nov 2027 A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Phase 3Recruiting 18 Aug 2028 A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
Phase 1/2Recruiting 31 Mar 2029 GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) (JET-201)
Phase 1Active, not recruiting 8 Dec 2026 A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Phase 1Recruiting 7 Jan 2027 A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
Phase 1Active, not recruiting 31 Mar 2027 A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
Phase 1Recruiting 21 Jun 2027 A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
Phase 1Recruiting 31 Aug 2027 A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Phase 1Recruiting 30 Nov 2027 A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Pasritamig

Following is part of Solo: you see every change to Pasritamig the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in